[go: up one dir, main page]

DK1132403T3 - TGF G Beta1-inhibitorpeptider - Google Patents

TGF G Beta1-inhibitorpeptider

Info

Publication number
DK1132403T3
DK1132403T3 DK99957342T DK99957342T DK1132403T3 DK 1132403 T3 DK1132403 T3 DK 1132403T3 DK 99957342 T DK99957342 T DK 99957342T DK 99957342 T DK99957342 T DK 99957342T DK 1132403 T3 DK1132403 T3 DK 1132403T3
Authority
DK
Denmark
Prior art keywords
tgf
inhibitor peptides
compositions
manufacture
beta1
Prior art date
Application number
DK99957342T
Other languages
Danish (da)
English (en)
Inventor
Sagastibelza Juan Jose Lasarte
Valtuena Jesus Prieto
Saenz Ignacio Jose Ezquerro
Cuesta Francisco Borras
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of DK1132403T3 publication Critical patent/DK1132403T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK99957342T 1998-11-24 1999-11-23 TGF G Beta1-inhibitorpeptider DK1132403T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009802465A ES2146552B1 (es) 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31

Publications (1)

Publication Number Publication Date
DK1132403T3 true DK1132403T3 (da) 2006-08-14

Family

ID=8305903

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99957342T DK1132403T3 (da) 1998-11-24 1999-11-23 TGF G Beta1-inhibitorpeptider

Country Status (16)

Country Link
US (2) US7057013B1 (sl)
EP (1) EP1132403B1 (sl)
JP (5) JP3836677B2 (sl)
CN (1) CN1203091C (sl)
AT (1) ATE322505T1 (sl)
AU (1) AU767498B2 (sl)
BR (1) BR9915604B1 (sl)
CA (1) CA2352537C (sl)
CY (1) CY1105616T1 (sl)
DE (1) DE69930763T2 (sl)
DK (1) DK1132403T3 (sl)
ES (2) ES2146552B1 (sl)
PT (1) PT1132403E (sl)
RU (1) RU2232771C2 (sl)
SI (1) SI1132403T1 (sl)
WO (1) WO2000031135A1 (sl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
JP2002087938A (ja) * 2000-09-11 2002-03-27 Shiseido Co Ltd 養毛剤及びそのスクリーニング方法
EP1534737A4 (en) * 2002-04-29 2007-10-31 Univ Saint Louis PEPTIDANTAGONISTS OF MEMBERS OF THE TGF BETA FAMILY AND THEIR THERAPEUTIC APPLICATION
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20090263410A1 (en) * 2005-10-24 2009-10-22 Proyecto De Biomedicina Cima, S.L. Use of tgf-b1 inhibitor peptides in the preparation of an immune response modulating agent
RU2420307C2 (ru) * 2005-10-24 2011-06-10 Проекто Де Биомедисина Сима, С.Л. ПРИМЕНЕНИЕ ИНГИБИРУЮЩИХ TGF-бета1 ПЕПТИДОВ ДЛЯ ПРИГОТОВЛЕНИЯ МОДУЛИРУЮЩЕГО ИММУННЫЙ ОТВЕТ АГЕНТА
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Ｔｇｆｐ－ｃａｐ 펩타이드 및 그의 용도
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
EP2192904B1 (en) * 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
JP4630914B2 (ja) 2008-04-14 2011-02-09 株式会社日本ハイポックス 肝線維化抑制剤
WO2009150284A2 (es) 2008-06-13 2009-12-17 Proyecto De Biomedicina Cima, S.L. Conjugados de apo-a para la administración de compuestos biológicamente activos
US8487006B2 (en) 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
US20110294734A1 (en) 2009-02-05 2011-12-01 Digna Biotech, S.L. Pharmaceutical compositions comprising tgf-beta 1 inhibitor peptides
ES2347627B1 (es) 2009-03-06 2011-10-10 Isdin, S.A. Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
KR100983182B1 (ko) * 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
CA2780671A1 (en) 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Regulated expression system
RU2565539C2 (ru) * 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
CN103917659A (zh) 2011-09-05 2014-07-09 宝丽制药股份有限公司 Etfb在细胞异常增殖中的应用方法以及异常增殖抑制剂
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
HRP20200692T1 (hr) 2013-03-14 2020-08-07 The Brigham And Women's Hospital, Inc. Pripravci i postupci za ekspandiranje i kultiviranje epitelnih matičnih stanica
JP6403217B2 (ja) 2013-07-30 2018-10-10 京都府公立大学法人 角膜内皮ｅｃｍ治療薬
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
RU2712967C2 (ru) * 2013-10-31 2020-02-03 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума
EP3685848B1 (en) 2013-11-21 2021-09-15 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
AU2015296037B2 (en) * 2014-08-01 2021-04-29 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP6773645B2 (ja) 2014-09-03 2020-10-21 ザ ブリガム アンド ウィミンズ ホスピタル，インコーポレイテッド 聴覚障害の治療のための内耳毛細胞を生成するための組成物、システムおよび方法
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
WO2017120543A1 (en) 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
KR101841748B1 (ko) * 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
KR101791526B1 (ko) 2016-02-18 2017-11-01 (주)케어젠 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
JP7080179B2 (ja) 2016-03-15 2022-06-03 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大に関する方法および組成物
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
KR101954214B1 (ko) * 2017-05-23 2019-03-06 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN109432431B (zh) 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
KR102265432B1 (ko) 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
CN110511285B (zh) * 2019-08-27 2023-01-24 南京安吉生物科技有限公司 一种重组融合多肽及其应用
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
KR102779666B1 (ko) * 2020-12-23 2025-03-12 한국과학기술연구원 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도
KR20240000395A (ko) * 2022-06-22 2024-01-02 주식회사 유씨아이테라퓨틱스 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
JPH06500574A (ja) * 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
FR2720069A1 (fr) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Dérivés de facteurs de croissance et d'hormones de la superfamille des TGFB, procédé pour leur obtention et leurs applications biologiques.
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy

Also Published As

Publication number Publication date
CA2352537A1 (en) 2000-06-02
JP4002287B2 (ja) 2007-10-31
AU1507700A (en) 2000-06-13
JP3836677B2 (ja) 2006-10-25
CY1105616T1 (el) 2010-07-28
BR9915604B1 (pt) 2011-07-26
SI1132403T1 (sl) 2006-08-31
JP2008056685A (ja) 2008-03-13
US7057013B1 (en) 2006-06-06
CA2352537C (en) 2011-11-15
CN1328569A (zh) 2001-12-26
RU2232771C2 (ru) 2004-07-20
US7528226B2 (en) 2009-05-05
EP1132403A1 (en) 2001-09-12
EP1132403B1 (en) 2006-04-05
AU767498B2 (en) 2003-11-13
ES2262349T3 (es) 2006-11-16
US20070014767A1 (en) 2007-01-18
ES2146552B1 (es) 2001-04-16
JP4237807B2 (ja) 2009-03-11
JP4068654B2 (ja) 2008-03-26
ES2146552A1 (es) 2000-08-01
DE69930763T2 (de) 2006-11-30
ATE322505T1 (de) 2006-04-15
CN1203091C (zh) 2005-05-25
PT1132403E (pt) 2006-07-31
JP2002530431A (ja) 2002-09-17
DE69930763D1 (en) 2006-05-18
JP2009040796A (ja) 2009-02-26
WO2000031135A1 (es) 2000-06-02
JP2007186519A (ja) 2007-07-26
JP2006241166A (ja) 2006-09-14
JP4272255B2 (ja) 2009-06-03
BR9915604A (pt) 2001-08-07

Similar Documents

Publication Publication Date Title
DK1132403T3 (da) TGF G Beta1-inhibitorpeptider
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
EE9800306A (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
DE69938174D1 (de) Peptid zusammensetzungen und formulierungen unter verwendung derselben
ATE253063T1 (de) 5-ht1f-agonisten
ID26819A (id) Turunan imidazo piridina yang menghambat sekresi asam lambung
MX9303082A (es) Proteasa y componentes relacionados con el dna.
SE9802729D0 (sv) Novel Compounds
GB9806632D0 (en) Peptide factor
BR9803756A (pt) Polimento da unha antipsoriático.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
DE68907635D1 (de) Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
BR0207039A (pt) Polipeptìdeos de fusão da glicoproteìna ib alfa plaquetária e seus métodos de uso
NO20002408D0 (no) 5-HT1F antagonister
TR200200278T2 (tr) Kalsilitik bileşimler
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
DK1012286T3 (da) Allelvariant af humant STAT3
ATE282609T1 (de) Neue substituierte n-methyl-n-(4-(4-(1h- benzimidazol-2-yl) (1,4)diazepan-1-yl)-2- (aryl)butyl)benzamide zur behandlung von allergischen krankheiten
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
DE69719190D1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung
ZA989313B (en) Novel compounds for treating diseases associated with the biological effect of endothelin.
ITRM920516A0 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.